Cantargia (CANTA) investor relations material

Strategic focus and scientific rationale

• Targeting IL1RAP enables selective blocking of inflammatory pathways implicated in serious diseases, aiming for optimal efficacy without broad immunosuppression.

• IL1RAP acts as a co-receptor for IL1, IL33, and IL36, allowing versatile intervention across multiple disease-relevant pathways.

• Preclinical and clinical data support the approach in both oncology (MDS, AML, PDAC, NSCLC) and inflammatory diseases.

• The CANxx platform and pipeline, including bispecific and ADC candidates, are advancing, with new targets to be announced by year-end.

Clinical development and trial updates

• MDS/AML trials with MD Anderson Cancer Center show promising early results, including complete remissions in initial patients.

• New data from the MDS/AML study will be presented at ASH in November, with full data expected by December.

• PDAC phase 2A results show improved overall survival with nadunolimab plus chemotherapy compared to standard care.

• A combination study with daroxadrecept, recently approved for second-line PDAC, is planned, with first patient expected in Q1 2027.

• Full MDS/AML trial data readout is anticipated by mid-2027.

Competitive landscape and financial outlook

• MDS space has seen recent failures, with only one competitor (Faron Pharmaceuticals) slightly ahead; the field remains open for innovation.

• Financial position is strong following a recent capital raise, supporting ongoing and expanded clinical programs.

• Strategic investments are focused on expanding MDS/AML studies and combination trials in PDAC.

• Market entry is several years away, pending pivotal phase 2b/3 trials in both PDAC and MDS.